$53.97
-2.03-3.63%
Last update: Oct 16, 7:14 PM
$54.00
-2.00-3.57%
TG Therapeutics Inc
TGTXNASDAQ
TG Therapeutics (TGTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
TG Therapeutics (TGTX) last issued guidance on August 3, 2026 for fiscal year 2026. The company guided revenue in the range of $950M - $950M for the period.
Compared to prior guidance, TG Therapeutics raised its revenue forecast from a prior range of $925M - $925M.
TG Therapeutics has issued 10 guidance updates between January 14, 2025 and August 3, 2026. During this period, the company raised its outlook 7 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.43 | $0.27 | $0.34 | $0.22 |
| Actual | $0.05 | $0.18 | $0.14 | $2.43 |
| Surprise | -88.4% | -33.3% | -58.8% | +1004.6% |
| Revenue | ||||
| Estimate | $228.9M | $200.8M | $191.8M | $151.6M |
| Actual | $240.3M | $204.9M | $192.6M | $161.7M |
| Surprise | +4.98% | +2.03% | +0.42% | +6.69% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.28 | $0.40 | $0.54 | $0.71 |
| Revenue | ||||
| Consensus | $245.8M | $270.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $0.05 | $0.43 | -88.4 % |
| Q1 | May 6, 2026 | $0.18 | $0.27 | -33.3 % |
| Q4 | Feb 26, 2026 | $0.14 | $0.34 | -58.8 % |
| Q3 | Nov 3, 2025 | $2.43 | $0.22 | 1004.6 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $240.34M | $228.93M | 4.98 % |
| Q1 | May 6, 2026 | $204.92M | $200.83M | 2.03 % |
| Q4 | Feb 26, 2026 | $192.57M | $191.77M | 0.42 % |
| Q3 | Nov 3, 2025 | $161.71M | $151.57M | 6.69 % |
